Physician profile
Michael T Steelman
NPI 1033183454
$29,360.62
in general payments reported to CMS, 2019-2025
12 companies · $35.16 in 2025
The $35.16 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $8,962 · 2021: $98.95 · 2022: $243 · 2023: $196 · 2025: $35.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $28,896.02 | 2019-2025 | Sublocade |
| Alkermes, INC. | $152.85 | 2021-2023 | Vivitrol |
| Abbvie INC. | $62.91 | 2022-2023 | Vraylar |
| Novartis Pharmaceuticals Corporation | $47.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.99 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.43 | 2021-2022 | |
| Organon LLC | $28.66 | 2021-2022 | |
| Novo Nordisk INC | $27.69 | 2022-2023 | Wegovy |
| Gilead Sciences, INC. | $26.94 | 2023 | |
| Braeburn INC. | $18.19 | 2025 | Brixadi |
| Amgen INC. | $13.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Steelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.